Bevacizumab in combination with TMZ in patients with recurrent GBM: Final OS and PFS analysis.

2087 Background: BEV provides a consistent clinical benefit in the treatment of relapsing GBM in terms of a delayed progression and increased median overall survival compared to historical controls...